In silico identification and evaluation of new Trypanosoma cruzi trypanothione reductase (TcTR) inhibitors obtained from natural products database of the Bahia semi-arid region (NatProDB)

Trypanosoma cruzi Trypanothione Reductase (TcTR) is one of the therapeutic targets studied in the development of new drugs against Chagas' disease. Due to its biodiversity, Brazil has several compounds of natural origin that were not yet properly explored in drug discovery. Therefore, we employed the Virtual Screening against TcTR aiming to discover new inhibitors from the Natural Products Database of the Bahia Semi-Arid region (NatProDB). This database has a wide chemical diversity favoring the discovery of new chemical entities. Subsequently, we analyzed the best docking conformations using self-organizing maps (AuPosSOM) aiming to verify their interaction sites at TcTR. Finally, the Pred-hERG, the Aggregator Advisor, the FAF-DRUGS and the pkCSM results allowed us to evaluate, respectively, the cardiotoxicity, aggregation capacity, presence of false positives (PAINS) and its toxicity. Thus, we selected three molecules that could be tested in in vitro assays in the hope that the computational results reported here would favor the development of new anti-chagasic drugs.

[1]  Peer Bork,et al.  Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees , 2016, Nucleic Acids Res..

[2]  A. Fairlamb,et al.  Phenotype of recombinant Leishmania donovani and Trypanosoma cruzi which over-express trypanothione reductase. Sensitivity towards agents that are thought to induce oxidative stress. , 1993, European journal of biochemistry.

[3]  A. Fairlamb,et al.  Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress , 2000, Molecular microbiology.

[4]  Alexander Tropsha,et al.  Pred‐hERG: A Novel web‐Accessible Computational Tool for Predicting Cardiac Toxicity , 2015, Molecular informatics.

[5]  Martin Olivier,et al.  Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages , 1997, The EMBO journal.

[6]  P. Dorn,et al.  Autochthonous Transmission of Trypanosoma cruzi, Louisiana , 2007, Emerging infectious diseases.

[7]  M. Berriman,et al.  Crystal structure of Trypanosoma cruzi trypanothione reductase in complex with trypanothione, and the structure-based discovery of new natural product inhibitors. , 1999, Structure.

[8]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[9]  A. Fairlamb,et al.  Metabolism and functions of trypanothione in the Kinetoplastida. , 1992, Annual review of microbiology.

[10]  N. Andrews,et al.  The Trypanosoma cruzi–host-cell interplay: location, invasion, retention , 2005, Nature Reviews Microbiology.

[11]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998 .

[12]  R. Krauth-Siegel,et al.  Redox control in trypanosomatids, parasitic protozoa with trypanothione-based thiol metabolism. , 2008, Biochimica et biophysica acta.

[13]  Olivier Sperandio,et al.  FAF-Drugs2: Free ADME/tox filtering tool to assist drug discovery and chemical biology projects , 2008, BMC Bioinformatics.

[14]  A. Fairlamb,et al.  Down-regulation of Leishmania donovani trypanothione reductase by heterologous expression of a trans-dominant mutant homologue: effect on parasite intracellular survival. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Irwin,et al.  An Aggregation Advisor for Ligand Discovery. , 2015, Journal of medicinal chemistry.

[16]  M. O. Khan,et al.  Trypanothione Reductase: A Viable Chemotherapeutic Target for Antitrypanosomal and Antileishmanial Drug Design , 2007, Drug target insights.

[17]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[18]  P. Pascutti,et al.  Molecular Dynamics Simulations of Peptide Inhibitors Complexed With Trypanosoma cruzi Trypanothione Reductase , 2012, Chemical biology & drug design.

[19]  A. Ouaissi,et al.  Intracellular growth and metacyclogenesis defects in Trypanosoma cruzi carrying a targeted deletion of a Tc52 protein‐encoding allele , 1999, Molecular microbiology.

[20]  Guillaume Bouvier,et al.  Contact-based ligand-clustering approach for the identification of active compounds in virtual screening , 2012, Advances and applications in bioinformatics and chemistry : AABC.

[21]  Ricardo P. Rodrigues,et al.  Estratégias de Triagem Virtual no Planejamento de Fármacos , 2012 .

[22]  A. Fairlamb,et al.  Extrachromosomal, homologous expression of trypanothione reductase and its complementary mRNA in Trypanosoma cruzi. , 1996, Nucleic acids research.

[23]  A. L. Abreu-Silva,et al.  Oral Outbreak of Chagas Disease in Santa Catarina, Brazil: Experimental Evaluation of a Patient’s Strain , 2015, PloS one.

[24]  J J Baldwin,et al.  Prediction of drug absorption using multivariate statistics. , 2000, Journal of medicinal chemistry.

[25]  J. Silva,et al.  Quimioterapia da doença de Chagas: estado da arte e perspectivas no desenvolvimento de novos fármacos , 2009 .

[26]  V. Dubey,et al.  Screening natural products database for identification of potential antileishmanial chemotherapeutic agents , 2011, Interdisciplinary Sciences: Computational Life Sciences.

[27]  Guillaume Bouvier,et al.  Automatic clustering of docking poses in virtual screening process using self-organizing map , 2010, Bioinform..

[28]  J. Gasteiger,et al.  ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .

[29]  P. Colepicolo,et al.  New drugs with antiprotozoal activity from marine algae: a review , 2014 .

[30]  Douglas E. V. Pires,et al.  pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures , 2015, Journal of medicinal chemistry.

[31]  Alexander Tropsha,et al.  Tuning HERG out: antitarget QSAR models for drug development. , 2014, Current topics in medicinal chemistry.

[32]  A. Fairlamb,et al.  Evidence that trypanothione reductase is an essential enzyme in Leishmania by targeted replacement of the tryA gene locus , 1998, Molecular microbiology.

[33]  A Prata,et al.  Clinical and epidemiological aspects of Chagas disease. , 2001, The Lancet. Infectious diseases.

[34]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[35]  A. Fairlamb,et al.  Site-directed mutagenesis of the redox-active cysteines of Trypanosoma cruzi trypanothione reductase. , 1995, European journal of biochemistry.

[36]  D. Marks,et al.  Use of an additional hydrophobic binding site, the Z site, in the rational drug design of a new class of stronger trypanothione reductase inhibitor, quaternary alkylammonium phenothiazines , 2000 .

[37]  P. Hotez,et al.  Eliminating the Neglected Tropical Diseases: Translational Science and New Technologies , 2016, PLoS neglected tropical diseases.

[38]  Kenneth T. Douglas,et al.  Erratum: Phenothiazine inhibitors of trypanothione reductase as potenial antitrypanosomal and antileishmanial drugs (Journal of Medicinal Chemistry (1998) 41 (150)) , 1998 .

[39]  M. Botta,et al.  A fast virtual screening approach to identify structurally diverse inhibitors of trypanothione reductase. , 2011, Bioorganic & medicinal chemistry letters.

[40]  Thaís Oliveira da Silva,et al.  Síntese, avaliação biológica e modelagem molecular de arilfuranos como inibidores da enzima tripanotiona redutase , 2008 .

[41]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[42]  D Horvath,et al.  A virtual screening approach applied to the search for trypanothione reductase inhibitors. , 1997, Journal of medicinal chemistry.

[43]  A. Fairlamb,et al.  Substrate interactions between trypanothione reductase and N1-glutathionylspermidine disulphide at 0.28-nm resolution. , 1993, European journal of biochemistry.

[44]  Roque Aras Júnior,et al.  Acute Chagas disease outbreak associated with oral transmission. , 2008, Revista da Sociedade Brasileira de Medicina Tropical.

[45]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[46]  W. Setzer,et al.  The potential of secondary metabolites from plants as drugs or leads against protozoan neglected diseases - part II. , 2012, Current medicinal chemistry.